[go: up one dir, main page]

WO2005009394A3 - Drug delivery in the nervous system - Google Patents

Drug delivery in the nervous system Download PDF

Info

Publication number
WO2005009394A3
WO2005009394A3 PCT/US2004/024104 US2004024104W WO2005009394A3 WO 2005009394 A3 WO2005009394 A3 WO 2005009394A3 US 2004024104 W US2004024104 W US 2004024104W WO 2005009394 A3 WO2005009394 A3 WO 2005009394A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
drug delivery
nervous system
nerve
tissues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/024104
Other languages
French (fr)
Other versions
WO2005009394A2 (en
Inventor
Michael Russell
Yongjin Hou
Carl Cotman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aaken Laboratories Inc
Original Assignee
Aaken Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aaken Laboratories Inc filed Critical Aaken Laboratories Inc
Publication of WO2005009394A2 publication Critical patent/WO2005009394A2/en
Anticipated expiration legal-status Critical
Publication of WO2005009394A3 publication Critical patent/WO2005009394A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides compositions useful for transporting agents to target cells or tissues, e.g., nerve cells via nerve transport. The present invention also provides methods of using the compositions provided by the present invention to deliver therapeutic agents for the treatment of neurologically related disorders.
PCT/US2004/024104 2003-07-24 2004-07-26 Drug delivery in the nervous system Ceased WO2005009394A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/626,351 US20050027110A1 (en) 2003-07-24 2003-07-24 Drug delivery in the nervous system
US10/626,351 2003-07-24

Publications (2)

Publication Number Publication Date
WO2005009394A2 WO2005009394A2 (en) 2005-02-03
WO2005009394A3 true WO2005009394A3 (en) 2007-11-08

Family

ID=34103237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024104 Ceased WO2005009394A2 (en) 2003-07-24 2004-07-26 Drug delivery in the nervous system

Country Status (2)

Country Link
US (1) US20050027110A1 (en)
WO (1) WO2005009394A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302402B1 (en) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. USE OF A CYTOQUINE OF THE INTERLEUQUINA-6 FAMILY IN THE PREPARATION OF A COMPOSITION FOR ADMINISTRATION COMBINED WITH INTERFERON-ALFA.
WO2007047922A2 (en) * 2005-10-19 2007-04-26 Smartcells, Inc. Polymer-drug conjugates
EP1985311A4 (en) * 2006-01-24 2011-04-13 Univ Kagoshima AGENT FOR TARGETING A MEDICATION ON A CEREBRAL NEURONE
US20070237722A1 (en) * 2006-03-28 2007-10-11 Peyman Gholam A Neural conduit agent dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
CN101820896A (en) 2007-06-08 2010-09-01 麻省理工学院 IGF for Rett Syndrome and Synaptic Disorders
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
AU2011336470B8 (en) 2010-12-01 2017-09-14 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP2854834A4 (en) 2012-05-30 2016-05-18 Biostrategies LC PLANT LECTINES AS AN EXCIPIENT OF RELATED MEDICINAL SUBSTANCES IN ANIMAL AND HUMAN CELLS
US10093708B2 (en) 2013-09-24 2018-10-09 Medicenna Therapeutics Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
US9890288B2 (en) 2015-12-08 2018-02-13 U.S. Silica Company Solar reflective particulates
US11529389B2 (en) * 2018-03-09 2022-12-20 University of Pittsburgh—of the Commonwealth System of Higher Education Delivering biological drugs to tissues
US11041018B2 (en) * 2018-06-08 2021-06-22 The Chinese University Of Hong Kong Agglutination of gangliosides for treating alzheimer's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURTIS R. ET AL.: "Neuronal Injury Increases Retrograde Axonal Transport of the Neurotrophins to Spinal Sensory Neurons and Motor Neurons via Multiple Receptor Mechanisms", MOL. CELL NEUROSCI., vol. 12, 1998, pages 105 - 118 *
RUSSELL M. ET AL.: "Nerve transport of WGA-NGF to the brain prevents cell death", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, October 1997 (1997-10-01), pages 888 *

Also Published As

Publication number Publication date
WO2005009394A2 (en) 2005-02-03
US20050027110A1 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
WO2008054544A3 (en) Method for delivery across the blood brain barrier
WO2005009394A3 (en) Drug delivery in the nervous system
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2005107726A3 (en) Method for the treatment of back pain
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2007022470A3 (en) Methods and compositions for treating neurological disease
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
CA2514473A1 (en) Fused bicyclic nitrogen-containing heterocycles
WO2005046603A3 (en) Pyridine compounds
UA94097C2 (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors
ATE459357T1 (en) COMBINATIONS FOR TREATING MULTIPLE MYELOMA
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
TW200531689A (en) Therapeutic agents
WO2005000215A3 (en) Methods for treating pain
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX2011001384A (en) Compositions and methods for treating psychiatric disorders.
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
TW200635903A (en) Therapeutic agents
DK1545537T3 (en) Alpha-7 nicotine receptor agonists and statins in combination
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase